CME Grant Requests

Below is what we need in order to review CME grant requests supported by EUSA Pharma Medical Affairs:

Packets should be emailed to medinfo-us@eusapharma.com or mailed to the corporate offices at:

Medical Affairs Department
EUSA Pharma (USA), Inc.
One Summit Square
1717 Langhorne Newtown Road, Suite 201
Langhorne, PA 19047

In order to allow adequate time for receipt and review of the request, please allow a minimum of 4 weeks prior to the proposed event for processing.

CONTRAINDICATIONS: Hx of serious hypersensitivity to Erwinaze, including anaphylaxis; Hx of serious pancreatitis, thrombosis or hemorrhage with prior L-asparaginase therapy.

WARNINGS AND PRECAUTIONS: Discontinue if serious hypersensitivity, including anaphylaxis, OR severe or hemorrhagic pancreatitis occur. Monitor glucose (intolerance may not be reversible); With thrombosis and hemorrhage: discontinue until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women.

COMMON (≥ 1%) ADVERSE REACTIONS: Serious hypersensitivity, including anaphylaxis, pancreatitis, abnormal transaminases, coagulation abnormalities, nausea, vomiting, and hyperglycemia.

Please see full Prescribing Information.

This site is only intended for residents of the United States.